Molecular Detection of Gastrointestinal Neoplasia: Innovations in Early Detection and Screening

Gastroenterology Clinics of North America

Volumn 45, Issue 3, 2016, Pages 529-542

  Anderson, Bradley W ^a   Ahlquist, David A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Blood testing; Early detection; Gastrointestinal cancer; Molecular markers; Screening; Stool testing

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD1D ANTIGEN; DNA; RNA; TUMOR MARKER;

BARRETT ESOPHAGUS; BLOOD ANALYSIS; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; CYST FLUID; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM CANCER; DISEASE SURVEILLANCE; DNA DETERMINATION; EARLY DIAGNOSIS; ESOPHAGUS CANCER; FECES ANALYSIS; HUMAN; INFLAMMATORY BOWEL DISEASE; LIVER CANCER; MASS SCREENING; MOLECULAR DIAGNOSIS; PANCREAS CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; STOMACH LAVAGE; TUMOR CELL; CHEMISTRY; COLORECTAL NEOPLASMS; CYTOLOGY; EARLY CANCER DIAGNOSIS; ESOPHAGEAL NEOPLASMS; FECES; GASTROINTESTINAL NEOPLASMS; GENETICS; METABOLISM; PANCREAS JUICE; PANCREATIC NEOPLASMS; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DNA, NEOPLASM; EARLY DETECTION OF CANCER; ESOPHAGEAL NEOPLASMS; FECES; GASTRIC LAVAGE; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOPLASTIC CELLS, CIRCULATING; PANCREATIC JUICE; PANCREATIC NEOPLASMS; RNA, NEOPLASM;

EID: 84991256730     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2016.04.009     Document Type: Review

References (80)

1. 1 Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:5 (2015), E359–E386.
2. 2 Torre, L.A., Bray, F., Siegel, R.L., et al. Global cancer statistics, 2012. CA Cancer J Clin 65:2 (2015), 87–108.
3. 3 Simard, E.P., Ward, E.M., Siegel, R., et al. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 62:2 (2012), 118–128.
4. 4 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66:1 (2016), 7–30.
5. 5 Rahib, L., Smith, B.D., Aizenberg, R., et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:11 (2014), 2913–2921.
6. 6 Bowles, M.J., Benjamin, I.S., ABC of the upper gastrointestinal tract: cancer of the stomach and pancreas. BMJ 323:7326 (2001), 1413–1416.
7. 7 Zou, H., Pan-detection of gastrointestinal neoplasms by stool DNA testing: establishment of feasibility. Gastroenterology, 136, 2009, A625 [abstract: #T2036].
8. 8 Ahlquist, D.A., Taylor, W.R., Mahoney, D.W., et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol 10:3 (2012), 272–277.e1.
9. 9 Grutzmann, R., Molnar, B., Pilarsky, C., et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One, 3(11), 2008, e3759.
10. 10 Ahlquist, D.A., Next-generation stool DNA testing: expanding the scope. Gastroenterology 136:7 (2009), 2068–2073.
11. 11 Ahlquist, D.A., Harrington, J.J., Burgart, L.J., et al. Morphometric analysis of the “mucocellular layer” overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol 31:1 (2000), 51–57.
12. 12 Grasso, L., Wyss, R., Weidenauer, L., et al. Molecular screening of cancer-derived exosomes by surface plasmon resonance spectroscopy. Anal Bioanal Chem 407:18 (2015), 5425–5432.
13. 13 Strauss, B.B., Yab, T.C., O'Connor, H.M., et al. Fecal recovery of ingested cellular DNA: implications for noninvasive detection of upper gastrointestinal neoplasms. Dig Dis Sci 61:1 (2016), 117–125.
14. 14 Kisiel, J.B., Yab, T.C., Taylor, W.R., et al. Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates. Cancer 118:10 (2012), 2623–2631.
15. Caldas, C., Hahn, S.A., Hruban, R.H., et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 54:13 (1994), 3568–3573.
16. 16 Karachaliou, N., Mayo-de-Las-Casas, C., Molina-Vila, M.A., et al. Real-time liquid biopsies become a reality in cancer treatment. Ann Transl Med, 3(3), 2015, 36.
17. 17 Bettegowda, C., Sausen, M., Leary, R.J., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med, 6(224), 2014, 224ra24.
18. 18 Wong, S.C., Chan, C.M., Ma, B.B., et al. Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res 15:3 (2009), 1005–1012.
19. 19 Limburg, P.J., Immunomagnetic isolation of malignant colonocytes from stool - Feasibility study in model system. Gastroenterology, 110(4), 1996, A551.
20. 20 Koga, Y., Yasunaga, M., Moriya, Y., et al. Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis. Cancer Sci 99:10 (2008), 1977–1983.
21. 21 Duffy, M.J., Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin Chem 47:4 (2001), 624–630.
22. 22 Pavai, S., Yap, S.F., The clinical significance of elevated levels of serum CA 19-9. Med J Malaysia 58:5 (2003), 667–672.
23. 23 Hong, W.S., Hong, S.I., Clinical usefulness of alpha-1-antitrypsin in the diagnosis of hepatocellular carcinoma. J Korean Med Sci 6:3 (1991), 206–213.
24. 24 Thomas, D.S., Fourkala, E.O., Apostolidou, S., et al. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br J Cancer 113:2 (2015), 268–274.
25. 25 Kim, J.E., Lee, K.T., Lee, J.K., et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 19:2 (2004), 182–186.
26. 26 Witwer, K.W., Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin Chem 61:1 (2015), 56–63.
27. 27 Etheridge, A., Lee, I., Hood, L., et al. Extracellular microRNA: a new source of biomarkers. Mutat Res 717:1–2 (2011), 85–90.
28. 28 Yang, H., Xia, B.Q., Jiang, B., et al. Diagnostic value of stool DNA testing for multiple markers of colorectal cancer and advanced adenoma: a meta-analysis. Can J Gastroenterol 27:8 (2013), 467–475.
29. 29 Okugawa, Y., Grady, W.M., Goel, A., Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology 149:5 (2015), 1204–1225.e12.
30. 30 Kisiel, J.B., Taylor, W.R., Yab, T.C., et al. Accurate site prediction of gastrointestinal cancer by novel methylated DNA markers: discovery & validation. Cancer Res, 75, 2015, 4252.
31. 31 Zhang, Y., Epidemiology of esophageal cancer. World J Gastroenterol 19:34 (2013), 5598–5606.
32. 32 Napier, K.J., Scheerer, M., Misra, S., Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol 6:5 (2014), 112–120.
33. 33 Kadri, S.R., Lao-Sirieix, P., O'Donovan, M., et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ, 341, 2010, c4372.
34. 34 Hayeck, T.J., Kong, C.Y., Spechler, S.J., et al. The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus 23:6 (2010), 451–457.
35. Ross-Innes, C.S., Debiram-Beecham, I., O'Donovan, M., et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study. PLoS Med, 12(1), 2015, e1001780.
36. 36 Benaglia, T., Sharples, L.D., Fitzgerald, R.C., et al. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. Gastroenterology 144:1 (2013), 62–73.e6.
37. 37 Iyer, P., Johnson, M.L., Lansing, R., et al. Discovery, validation and feasibility testing of highly discriminant DNA methylation markers for detection of Barrett's esophagus using a capsule sponge device. Gastroenterol 150:4 (2016), S66–S67.
38. 38 Fels Elliott, D.R., Fitzgerald, R.C., Molecular markers for Barrett's esophagus and its progression to cancer. Curr Opin Gastroenterol 29:4 (2013), 437–445.
39. 39 Iyer PG. Detection of Barrett's dysplasia by assay of methylated DNA markers on whole esophageal brushings: a prospective feasibility study. Gastroenterology 2015;148(4):S-16.
40. 40 Roshandel, G., Merat, S., Sotoudeh, M., et al. Pilot study of cytological testing for oesophageal squamous cell dysplasia in a high-risk area in Northern Iran. Br J Cancer 111:12 (2014), 2235–2241.
41. 41 Jin, Z., Jiang, W., Wang, L., Biomarkers for gastric cancer: Progression in early diagnosis and prognosis (Review). Oncol Lett 9:4 (2015), 1502–1508.
42. 42 Zhu, C., Ren, C., Han, J., et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer 110:9 (2014), 2291–2299.
43. 43 Anderson, B.W., Suh, Y., Choi, B., et al. Gastric cancer detection by novel methylated DNA markers: Tissue validation in patient cohorts from the United States and South Korea. Am J Gastro, 110, 2015, S1033.
44. 44 Watanabe, Y., Kim, H.S., Castoro, R.J., et al. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology 136:7 (2009), 2149–2158.
45. 45 Kisiel, J.B., Raimondo, M., Taylor, W.R., et al. New DNA methylation markers for pancreatic cancer: discovery, tissue validation, and pilot testing in pancreatic juice. Clin Cancer Res 21:19 (2015), 4473–4481.
46. 46 Singhi, A.D., Zeh, H.J., Brand, R.E., et al. American Gastroenterological Association guidelines are inaccurate in detecting pancreatic cysts with advanced neoplasia: a clinicopathologic study of 225 patients with supporting molecular data. Gastrointest Endosc 83:6 (2016), 1107–1117.e2.
47. 47 Jana, T., Shroff, J., Bhutani, M.S., Pancreatic cystic neoplasms: review of current knowledge, diagnostic challenges, and management options. J Carcinog, 14, 2015, 3.
48. 48 Springer, S., Wang, Y., Dal Molin, M., et al. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology 149:6 (2015), 1501–1510.
49. 49 Wang, J., Paris, P.L., Chen, J., et al. Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions. Cancer Lett 356:2 Pt B (2015), 404–409.
50. 50 Majumder, S., Taylor, W.R., Yab, T.C., et al. Detection of pancreatic high-grade dysplasia and cancer using novel methylated DNA markers: Discovery and tissue validation. Gastroenterol 150:4 (2016), S120–121.
51. 51 Catenacci, D.V., Chapman, C.G., Xu, P., et al. Acquisition of portal venous circulating tumor cells from patients with pancreaticobiliary cancers by endoscopic ultrasound. Gastroenterology 149:7 (2015), 1794–1803.e4.
52. Rhim, A.D., Thege, F.I., Santana, S.M., et al. Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. Gastroenterology 146:3 (2014), 647–651.
53. 53 Schultz, N.A., Dehlendorff, C., Jensen, B.V., et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 311:4 (2014), 392–404.
54. 54 Melo, S.A., Luecke, L.B., Kahlert, C., et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523:7559 (2015), 177–182.
55. 55 Jemal, A., Bray, F., Center, M.M., et al. Global cancer statistics. CA Cancer J Clin 61:2 (2011), 69–90.
56. 56 Blechacz, B.R., Gores, G.J., Cholangiocarcinoma. Clin Liver Dis 12:1 (2008), 131–150.
57. 57 Bowlus, C.L., Olson, K.A., Gershwin, M.E., Evaluation of indeterminate biliary strictures. Nature reviews. Gastroenterol Hepatol 13:1 (2016), 28–37.
58. 58 Barr Fritcher, E.G., Voss, J.S., Brankley, S.M., et al. An optimized set of fluorescence in situ hybridization probes for detection of pancreatobiliary tract cancer in cytology brush samples. Gastroenterology 149:7 (2015), 1813–1824.e1.
59. 59 Ghoz, H.M., DNA methylation markers for detection of extrahepatic cholangiocarcinoma: discover, tissue validation, and pilot testing in biliary brush samples. Hepatology, 62(S1), 2015, 295A.
60. 60 Shen, J., Wang, S., Zhang, Y.J., et al. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology 55:6 (2012), 1799–1808.
61. 61 Ammerpohl, O., Pratschke, J., Schafmayer, C., et al. Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 130:6 (2012), 1319–1328.
62. 62 Goeppert, B., Konermann, C., Schmidt, C.R., et al. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. Hepatology 59:2 (2014), 544–554.
63. 63 Hu, L., Chen, G., Yu, H., et al. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int 4:1 (2010), 423–432.
64. 64 Zhang, P., Wen, X., Gu, F., et al. Methylation profiling of serum DNA from hepatocellular carcinoma patients using an Infinium Human Methylation 450 BeadChip. Hepatol Int 7:3 (2013), 893–900.
65. 65 Wen, Y., Han, J., Chen, J., et al. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int J Cancer 137:7 (2015), 1679–1690.
66. 66 Lin, X.J., Chong, Y., Guo, Z.W., et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol 16:7 (2015), 804–815.
67. 67 Chen S, Jain S, Lin S, et al. Development of a urine DNA based marker panel for early detection of liver cancer. Proceedings: AACR Annual Meeting 2014. San Diego (CA), April 5–9, 2014.
68. 68 Haggar, F.A., Boushey, R., Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22:4 (2009), 191–197.
69. 69 Smith, R.A., Manassaram-Baptiste, D., Brooks, D., et al. Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin 65:1 (2015), 30–54.
70. 70 Ahlquist, D.A., Zou, H., Domanico, M., et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 142:2 (2012), 248–256 [quiz: e25–6].
71. Lidgard, G.P., Domanico, M.J., Bruinsma, J.J., et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol 11:10 (2013), 1313–1318.
72. 72 Imperiale, T.F., Ransohoff, D.F., Itzkowitz, S.H., Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 371:2 (2014), 187–188.
73. 73 Kelly, J.J., Alberts, S.R., Sacco, F., et al. Colorectal cancer in Alaska native people, 2005-2009. Gastrointest Cancer Res 5:5 (2012), 149–154.
74. 74 Redwood, D.G., Asay, E.D., Blake, I.D., et al. Stool DNA testing for screening detection of colorectal neoplasia in Alaska native people. Mayo Clin Proc 91:1 (2016), 61–70.
75. 75 Kisiel, J.B., Yab, T.C., Nazer Hussain, F.T., et al. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther 37:5 (2013), 546–554.
76. 76 Lofton-Day, C., Model, F., Devos, T., et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 54:2 (2008), 414–423.
77. 77 Pedersen, S.K., Symonds, E.L., Baker, R.T., et al. Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC Cancer, 15, 2015, 654.
78. 78 Ogata-Kawata, H., Izumiya, M., Kurioka, D., et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One, 9(4), 2014, e92921.
79. 79 Rosenfeld, N., Aharonov, R., Meiri, E., et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26:4 (2008), 462–469.
80. 80 Nagasaka, T., Tanaka, N., Cullings, H.M., et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst 101:18 (2009), 1244–1258.